Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704949 | 0.89 | KMT2A (0.42) | MAPTALDH1A1GPR119CTSBKMT2A | |
| SCHEMBL389236 | 0.88 | MAPT (0.53) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL388810 | 0.85 | GPR119 (0.51) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL389055 | 0.84 | GPR119 (0.58) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL389089 | 0.83 | MAPT (0.61) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL389349 | 0.83 | GPR119 (0.52) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL389221 | 0.82 | GPR119 (0.51) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL390990 | 0.82 | GPR119 (0.70) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL390386 | 0.82 | GPR119 (0.51) | MAPTALDH1A1GPR119CTSBTP53 | |
| SCHEMBL389244 | 0.82 | GPR119 (0.49) | MAPTALDH1A1GPR119CTSBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606282-B1 | PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | ARENA PHARM INC (US) | 2008-11-12 | — | — | EP | claimed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| US-8198232-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8030270-B2 | Methods for identifying GLP-1 secretagogues | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8022034-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8003597-B2 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2322151-A2 | Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor | Arena Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100298333-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1997484-A2 | Method of identifying GLP-1 secretagogues | Arena Pharmaceuticals, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1606282-B1 | PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | ARENA PHARM INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1808168-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | Arena Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | MAPT 4045/4885ALDH1A1 2154/4885GPR119 2/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | MAPT 4045/4885ALDH1A1 2154/4885GPR119 2/4885 |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | GPR119, PC, PLPBP | MAPT 3871/4885ALDH1A1 260/4885GPR119 1/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | MAPT 4045/4885ALDH1A1 2154/4885GPR119 2/4885 |
| US-20100298333-A1 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | GLP1R, GPR119, GIPR | MAPT 4045/4885ALDH1A1 2154/4885GPR119 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.